

## UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO. FILING DATE F		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/698,320	10/31/2003	Harun Takruri	VFORGE.006C1	9821
20995	7590 04/21/2005		EXAMINER	
	MARTENS OLSON &	FAY, ZOHREH A		
2040 MAIN FOURTEEN		ART UNIT	PAPER NUMBER	
IRVINE, CA 92614			1618	
			DATE MAILED: 04/21/200	5

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Commons		Ap	plication No.	Applicant(s)	Applicant(s)			
		10	)/698,320	TAKRURI, HARI	TAKRURI, HARUN			
Office Action Summary			aminer	Art Unit				
			hreh Fay	1618				
Period fo	The MAILING DATE of this communica or Reply	tion appears	on the cover sheet	with the correspondence a	address			
THE - External after - If the - If NO - Failur	ORTENED STATUTORY PERIOD FOR MAILING DATE OF THIS COMMUNICA asions of time may be available under the provisions of 3 SIX (6) MONTHS from the mailing date of this communic period for reply specified above is less than thirty (30) day period for reply is specified above, the maximum statutore to reply within the set or extended period for reply will, eply received by the Office later than three months after and patent term adjustment. See 37 CFR 1.704(b).	ATION. 7 CFR 1.136(a). cation. ays, a reply withing y period will app by statute, cause	In no event, however, may n the statutory minimum of oly and will expire SIX (6) N e the application to become	v a reply be timely filed thirty (30) days will be considered tim IONTHS from the mailing date of this ABANDONED (35 U.S.C. § 133).	iely. communication.			
Status								
1)	Responsive to communication(s) filed of	on						
2a)□	This action is <b>FINAL</b> . 2b)⊠ This action is non-final.							
3)□	Since this application is in condition for allowance except for formal matters, prosecution as to the ments is							
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Dispositi	on of Claims							
5)□ 6)⊠ 7)□	Claim(s) <u>1-18</u> is/are pending in the apple 4a) Of the above claim(s) is/are vectoring is/are allowed.  Claim(s) <u>1-18</u> is/are rejected.  Claim(s) is/are objected to.  Claim(s) are subject to restriction	vithdrawn fr						
Applicati	on Papers							
9)□	The specification is objected to by the E	xaminer.						
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.								
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
11)	Replacement drawing sheet(s) including the The oath or declaration is objected to by		•	* · · ·	` '			
Priority u	nder 35 U.S.C. § 119							
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>								
Attachment	· •							
1) ⊠ Notice 2) □ Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-	948)	D	v Summary (PTO-413) o(s)/Mail Date				
3) 🛛 Inforn	nation Disclosure Statement(s) (PTO-1449 or PTC No(s)/Mail Date	D/SB/08)	5)  Notice o	f Informal Patent Application (PT	O-152)			

Application/Control Number: 10/698,320

**Art Unit: 1618** 

Claims 1-18 are presented for examination.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim18 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 18 is indefinite as to the expression "formulations of table 1". A claim has to be self-explanatory and cannot rely on a table in the specification.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 1-18 are rejected under 35 U.S.C. 103(a) as being unpatentable over Laties et al. (U.S. Patent 5,122,522) in view of Gwon et al. (U.S Patent 6,164,282) and Swaya (U.S. Patent 5,888,493).

Laties et al. Teach the use of pirenzepine for the treatment of myopia. See claims 1-3. The primary reference differs from the claimed invention in the presence of cellulose derivatives and other ingredients such as benzalkonium chloride claimed in claim 8. Gwon et al teach the addition methyl cellulose and the components claimed in claim 8 to the pirenzepine as old. See column 5 lines 35-50. Sawaya teaches that cellulose derivatives at the claimed viscosity have been previously used in ophthalmic aqueous gel formulation. See the abstract and claims 1-12. The addition of ophthalmic active ingredients to such gel composition is also taught by the above reference. See column 4, lines45-68 and column 5, lines 1-12. It would have been obvious to a person skilled in the art to incorporate cellulose derivative at the claimed viscosity into the teachings of the primary reference, considering that the secondary references teach the addition of cellulose derivative to pirenzepine as old, and also the preparation of cellulose derivatives at the claimed concentrations and viscosity in ophthalmic formulation as old.

One skilled in the art would have been motivated to combine the teachings of the above references, since one relates to the use of pirenzepine for the treatment of myopia and the other two relate to the use of cellulose in ophthalmic formulation in general, and in combination with pirenzepine specifically. The above references in combination make clear that pirenzepine has been previously uses for the treatment of myopia. Such references also make clear that the addition of cellulose derivatives at the claimed viscosity to ophthalmic formulations as old and well known. The sterilization or autoclaving pharmaceutical formulations are considered to be within the skill of the

Art Unit: 1618

artisan. To use different containers such as tubes for administration of ophthalmic formulation is also considered as old and well known. Applicant has presented no evidence to establish the unexpected or unobvious nature of the claimed invention, and as such, claims 1-18 are properly rejected under 35 U.S.C. 103.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Zohreh Fay whose telephone number is (571) 272-0573. The examiner can normally be reached on 9:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman Page can be reached on (571) 272-0602. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

ZOHREH FAY PRIMARY EXAMINER GROUP 1200

Z.F